Citations Report

Clinical Investigation : Citations & Metrics Report

Articles published in Clinical Investigation have been cited by esteemed scholars and scientists all around the world.

Clinical Investigation has got h-index 28, which means every article in Clinical Investigation has got 28 average citations.

Following are the list of articles that have cited the articles published in Clinical Investigation.

• Song G, Ivanova A. Enrollment and Stopping Rules for Managing Toxicity Requiring Long Follow-Up in Phase II Oncology Trials. Journal of biopharmaceutical statistics. 2015 Nov 2;25(6):1206-14. View at Publisher | View at Google Scholar | View at Indexing
• Antonijevic Z. Adaptive Clinical Trials. Clinical Investigation. 2015 Apr;5(4):353-4. View at Publisher | View at Google Scholar | View at Indexing
• Ivanova A, Paul B, Marchenko O, Song G, Patel N, Moschos SJ. Nine-year change in statistical design, profile, and success rates of Phase II oncology trials. Journal of Biopharmaceutical Statistics. 2016 Jan 2;26(1):141-9. View at Publisher | View at Google Scholar | View at Indexing
• Zhang Z, Chen R, Soon G, Zhang H. Treatment evaluation for a data?driven subgroup in adaptive enrichment designs of clinical trials. Statistics in medicine. 2018 Jan 15;37(1):1-1. View at Publisher | View at Google Scholar | View at Indexing
• Antonijevic Z. Adaptive Clinical Trials. Clinical Investigation. 2015 Apr;5(4):353-4. View at Publisher | View at Google Scholar | View at Indexing

• Lin J, Bunn V. Comparison of multi-arm multi-stage design and adaptive randomization in platform clinical trials. Contemporary Clinical Trials. 2017 Jan 13.

  View at Publisher | View at Google Scholar
• Urach S, Posch M. Multiâ€Âarm group sequential designs with a simultaneous stopping rule. Statistics in Medicine. 2016 Dec 30;35(30):5536-50. View at Publisher | View at Google Scholar | View at Indexing

• Lu X, He Y, Wu SS. Interval estimation in multi-stage drop-the-losers designs. Statistical methods in medical research. 2016 Mar 14:0962280215626748.

  View at Publisher | View at Google Scholar
• Dimairo M, Todd S, Julious S, Jaki T, Wason J, Hind D, Mander A, Weir C, Koenig F, Altman D, Nicholl J. ACE Project Protocol. Development of a CONSORT Extension for adaptive clinical trials. University of Sheffield View at Publisher | View at Google Scholar | View at Indexing
• Antonijevic Z. Adaptive Clinical Trials. Clinical Investigation. 2015 Apr;5(4):353-4. View at Publisher | View at Google Scholar | View at Indexing
• Antonijevic Z. Adaptive Clinical Trials. Clinical Investigation. 2015 Apr;5(4):353-4. View at Publisher | View at Google Scholar | View at Indexing
• Moran JL, Solomon PJ. New initiatives in critical care: distinguishing hype from hope. Critical Care and Resuscitation. 2016 Sep;18(3):141. View at Publisher | View at Google Scholar | View at Indexing
• Hu Y. Generalized Efron's biased coin design and its theoretical properties. Journal of Applied Probability. 2016 Jun 1;53(02):327-40. View at Publisher | View at Google Scholar | View at Indexing
• Gelhorn HL, Kulke MH, O’Dorisio T, Yang QM, Jackson J, Jackson S, Boehm KA, Law L, Kostelec J, Auguste P, Lapuerta P. Patient-reported symptom experiences in patients with carcinoid syndrome after participation in a study of telotristat etiprate: a qualitative interview approach. Clinical therapeutics. 2016 Apr 30;38(4):759-68. View at Publisher | View at Google Scholar | View at Indexing
• Goldberg DR, De Lombaert S, Aiello R, Bourassa P, Barucci N, Zhang Q, Paralkar V, Valentine J, Zavadoski W. Discovery of spirocyclic proline tryptophan hydroxylase-1 inhibitors. Bioorganic & medicinal chemistry letters. 2016 Feb 15;26(4):1124-9. View at Publisher | View at Google Scholar | View at Indexing
• Kulke MH, Hörsch D, Caplin ME, Anthony LB, Bergsland E, Öberg K, Welin S, Warner RR, Lombard-Bohas C, Kunz PL, Grande E. Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome. Journal of Clinical Oncology. 2016 Oct 31;35(1):14-23. View at Publisher | View at Google Scholar | View at Indexing
• Lamarca A, Barriuso J, McNamara MG, Hubner RA, Valle JW. Telotristat ethyl: a new option for the management of carcinoid syndrome. Expert Opinion on Pharmacotherapy. 2016 Dec 11;17(18):2487-98. View at Publisher | View at Google Scholar | View at Indexing
• Patel D, Chan D, Cehic G, Pavlakis N, Price TJ. Systemic therapies for advanced gastroenteropancreatic neuroendocrine tumors. Expert Review of Endocrinology & Metabolism. 2016 Jul 3;11(4):311-27. View at Publisher | View at Google Scholar | View at Indexing
• Anjo C, Mascaro Jr JM, Espinosa G, Cervera R. Effectiveness and safety of belimumab in patients with systemic lupus erythematosus in a real-world setting. Scandinavian journal of rheumatology. 2019 Nov 2;48(6):469-73. View at Publisher | View at Google Scholar | View at Indexing
• Bahaoddini, A. and Sangy, S., 2021. The effect of inflammation in MIA-induced osteoarthritis on physiological cardiovascular function in male rats. Academic Journal of Health Sciencies: Medicina balear, 36(4), pp.88-95. View at Publisher | View at Google Scholar | View at Indexing
• Uckun, Fatih M., James Carlson, Cemal Orhan, Joy Powell, Natalie M. Pizzimenti, Hendrik van Wyk, Ibrahim H. Ozercan, Michael Volk, and Kazim Sahin. "Rejuveinix Shows a Favorable Clinical Safety Profile in Human Subjects and Exhibits Potent Preclinical Protective Activity in the Lipopolysaccharide-Galactosamine Mouse Model of Acute Respiratory Distress Syndrome and Multi?Organ Failure." Frontiers in pharmacology 11 (2020): 1682. View at Publisher | View at Google Scholar | View at Indexing
• Uckun FM, Orhan C, Powell J, Sahin E, Ozercan IH, Volk M, Sahin K. Non-clinical safety profile and pharmacodynamics of two formulations of the anti-sepsis drug candidate Rejuveinix (RJX). Biomedicine & Pharmacotherapy. 2021 Sep 1;141:111823. View at Publisher | View at Google Scholar | View at Indexing
• Uckun FM, Orhan C, Powell J, Sahin E, Ozercan IH, Volk M, Sahin K. Non-clinical safety profile and pharmacodynamics of two formulations of the anti-sepsis drug candidate Rejuveinix (RJX). Biomedicine & Pharmacotherapy. 2021 Sep 1;141:111823. View at Publisher | View at Google Scholar | View at Indexing
• Uckun FM, Tuzcu M, Gitterle M, Volk M, Sahin K. Rejuveinix Mitigates Sepsis-Associated Oxidative Stress in the Brain of Mice: Clinical Impact Potential in COVID-19 and Nervous System Disorders. bioRxiv. 2021 Jan 1. View at Publisher | View at Google Scholar | View at Indexing
• Uckun FM, Ozercan IH, Orhan C, Gitterle M, Sahin K. Rejuveinix Reverses Severe Inflammatory Lung Damage in a Mouse Model of Fatal Sepsis. bioRxiv. 2021 Jan 1:2020-12. View at Publisher | View at Google Scholar | View at Indexing
• Uckun FM, Tuzcu M, Gitterle M, Volk M, Sahin K. Rejuveinix Mitigates Sepsis-Associated Oxidative Stress in the Brain: Clinical Impact Potential in COVID-19 and Nervous System Disorders. View at Publisher | View at Google Scholar | View at Indexing
• Uckun FM, Tuzcu M, Gitterle M, Volk M, Sahin K. Rejuveinix Mitigates Sepsis-Associated Oxidative Stress in the Brain: Clinical Impact Potential in COVID-19 and Nervous System Disorders. View at Publisher | View at Google Scholar | View at Indexing
• Santi Laurini, Francesco. "Conta ecografica 3D (SONOAVC) VS 2D dei follicoli ovarici in pazienti con endometriomi di elevate dimensioni sottoposte a fertilizzazione in vitro." (2021). View at Publisher | View at Google Scholar | View at Indexing
• Bark, Claire, Chloe Brown, and Per Svangren. "Systematic literature review of long-term efficacy data for topical psoriasis treatments." Journal of Dermatological Treatment (2021): 1-11. View at Publisher | View at Google Scholar | View at Indexing
• Reitamo, Sakari, and Anita Remitz. "Topical agents for atopic dermatitis." Advances in the Management of Atopic Dermatitis. Future medicine ltd, 2013. 62-72. View at Publisher | View at Google Scholar | View at Indexing
• Lee, Kyoungwon. The role of social class models in the relationship between socioeconomic status and academic achievement. University of Minnesota, 2009. View at Publisher | View at Google Scholar | View at Indexing
• Infectious Diseases Society of America (IDSA). "Combating antimicrobial resistance: policy recommendations to save lives." Clinical Infectious Diseases 52.suppl_5 (2011): S397-S428. View at Publisher | View at Google Scholar | View at Indexing
• Scarafile, Giancarlo. "Antibiotic resistance: current issues and future strategies." Reviews in Health Care 7.1 (2016): 3-16. View at Publisher | View at Google Scholar | View at Indexing
• Cristinacce, Andrew, et al. "A retrospective analysis of probability of target attainment in community-acquired pneumonia: ceftaroline fosamil versus comparators." Infectious diseases and therapy 8.2 (2019): 185-198. View at Publisher | View at Google Scholar | View at Indexing
• Bassetti, Matteo, et al. "A look at clinical trial design for new antimicrobials for the adult population." Expert review of clinical pharmacology 12.11 (2019): 1037-1046. View at Publisher | View at Google Scholar | View at Indexing
• Bart, Stephen M., et al. "Concordance of Early and Late End Points for Community-acquired Bacterial Pneumonia Trials." Clinical Infectious Diseases 73.9 (2021): e2607-e2612. View at Publisher | View at Google Scholar | View at Indexing
• Phee, Lynette. Unorthodox Antimicrobial Combination Therapies for the Treatment of Multi-drug Resistant Gram-negative Infections. Diss. Queen Mary University of London, 2018. View at Publisher | View at Google Scholar | View at Indexing
• Aruwa, Christiana Eleojo. Characterisation of Opuntia phenolic extracts and enzymatic modification of selected compunds. Diss. 2019. View at Publisher | View at Google Scholar | View at Indexing
• Rost, Lauren M., et al. "Discordance among antibiotic prescription guidelines reflects a lack of clear best practices." Open forum infectious diseases. Vol. 8. No. 1. US: Oxford University Press, 2021. View at Publisher | View at Google Scholar | View at Indexing
• Aruwa, Christiana Eleojo. Characterisation of Opuntia phenolic extracts and enzymatic modification of selected compunds. Diss. 2019. View at Publisher | View at Google Scholar | View at Indexing
• Melchers, M. J., van Mil, A. C., & Mouton, J. W. (2015). In vitro activity of ceftolozane alone and in combination with tazobactam against extended-spectrum-β-lactamase-harboring Enterobacteriaceae. Antimicrobial agents and chemotherapy, 59(8), 4521-4525. View at Publisher | View at Google Scholar | View at Indexing
• Hanberger, Håkan, Christian G. Giske, and Helen Giamarellou. "When and how to cover for resistant gram-negative bacilli in severe sepsis and septic shock." Current infectious disease reports 13.5 (2011): 416-425. View at Publisher | View at Google Scholar | View at Indexing
• Elstein, Deborah, et al. "Outcome of pregnancies in women receiving velaglucerase alfa for G aucher disease." Journal of Obstetrics and Gynaecology Research 40.4 (2014): 968-975. View at Publisher | View at Google Scholar | View at Indexing
• Mehta, A., Belmatoug, N., Bembi, B., Deegan, P., Elstein, D., Göker-Alpan, Ö., ... & Hughes, D. (2017). Exploring the patient journey to diagnosis of Gaucher disease from the perspective of 212 patients with Gaucher disease and 16 Gaucher expert physicians. Molecular genetics and metabolism, 122(3), 122-129. View at Publisher | View at Google Scholar | View at Indexing
• Bennett, L. L., & Fellner, C. (2018). Pharmacotherapy of Gaucher disease: current and future options. Pharmacy and Therapeutics, 43(5), 274. View at Publisher | View at Google Scholar | View at Indexing
• Bennett, L. L., & Fellner, C. (2018). Pharmacotherapy of Gaucher disease: current and future options. Pharmacy and Therapeutics, 43(5), 274. View at Publisher | View at Google Scholar | View at Indexing
• Ibrahim, J., & Call, R. (2017). Letter to the Editor on “Enzyme Replacement or Substrate Reduction? A Review of Gaucher Disease Treatment Options”. Hospital pharmacy, 52(11), 725. View at Publisher | View at Google Scholar | View at Indexing
• Kuo, C. L. "Applications for activity-based probes in biomedical research on glycosidases." PhD diss., Leiden University, 2019. View at Publisher | View at Google Scholar | View at Indexing
• Daykin, E., Ryan, E., & Sidransky, E. (2021). Diagnosing neuronopathic Gaucher disease: New considerations and challenges in assigning Gaucher phenotypes. Molecular Genetics and Metabolism. View at Publisher | View at Google Scholar | View at Indexing
• Sevsek, A. Guanidinium Iminosugars as Glycosidase Inhibitors. Diss. Utrecht University, 2017. View at Publisher | View at Google Scholar | View at Indexing